Moxifloxacin

Alternative Names: Avelox

Moxifloxacin is a fluoroquinolone antibiotic commonly used to treat community-acquired pneumonia (CAP) caused by susceptible bacteria. It is particularly useful for atypical pneumonia caused by organisms such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.

As a fluoroquinolone, it has potential side effects of  QT prolongation (risk of arrhythmias), tendinitis/tendon rupture (higher risk in elderly), peripheral neuropathy, and Clostridium difficile infection (diarrhea)

Treatment Type: Prescription Medication

Treatment Class: N/A

Treatment Modality: N/A

Review Summary

4.0

1 Reviews

Preferred by 1 Reviewers

Based on the limited information provided, which includes only one review with a rating of 4 out of 5, Moxifloxacin appears to be an effective treatment for outpatient community-acquired pneumonia. However, with just a single review and no detailed content, it is difficult to draw a definitive conclusion about the overall effectiveness of this treatment.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
5.0
1 = Very Expensive 5 = Very Affordable

5.0

Very Affordable
Relief Speed
3.0
1 = No Relief 5 = Immediate Relief

3.0

Moderate Relief
Side Effects
3.0
1 = Intolerable Effect 5 = No Effect

3.0

Moderate Effect
Treatment Line
3.0
1 = Third-line or more 5 = First-line

3.0

Second Line

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

4.0

1 Reviews
5
0%
4
100%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the limited information provided, which includes only one review with a rating of 4 out of 5, Moxifloxacin appears to be an effective treatment for outpatient community-acquired pneumonia. However, with just a single review and no detailed content, it is difficult to draw a definitive conclusion about the overall effectiveness of this treatment.

Reviews

Filter by reviewer type Pro

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
2 months ago
An option for outpatient pneumonia when there’s a higher level of concern or need for broader coverage, including atypicals. Convenient as monotherapy, but should be used selectively. Important to weigh risks, especially QT prolongation and tendon rupture, before choosing it.
#VeryAffordable #CoveredByInsurance #ModerateRelief #ModerateEffect #Second-line #Rescue/EmergencyUse